Astrazeneca Ab

Jens Petersen

Matthew Wd Perry

Mickael Mogemark

Christian Tyrchan

Konstantinos Karabelas

Pavol Zlatoidsky

Antonios Nikitidis

Peter Bold

Ulf Borjesson

Nils Pemberton

Rhona Cox

Matthew Perry

Ulf BÖRJESSON

Disclosed herein is the compound (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino)thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one of the following structure: and/or pharmaceutically acceptable salts and/or pharmaceutical compositions thereof, which inhibit phosphatidylinositol 3-kinase (PI3K) activity.

(S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino) thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one as a phosphatidylinositol 3-kinase inhibitor

There are disclosed certain novel compounds (including pharmaceutically acceptable salts thereof), that inhibit phosphatidylinositol 3-kinase gamma (PI3K&#x3b4;) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

Inhibitors of phosphatidylinositol 3-kinase gamma

Growing community of inventors

Mölndal, Sweden

Jens Petersen